Hepsin promotes breast tumor growth signaling via the TGFβ‐EGFR axis
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Denis Belitškin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Research Programs Unit/Translational Cancer Medicine Research Program and Medicum, Faculty of Medicine, University of Helsinki, Finland. Hauptthemen laut MEDLINE: Breast Neoplasms, Epidermal Growth Factor, Serine Endopeptidases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepsin, a type II transmembrane serine protease, is commonly overexpressed in prostate and breast cancer. The hepsin protein is stabilized by the Ras‐MAPK pathway, and, downstream, this protease regulates the degradation of extracellular matrix components and activates growth factor pathways, such as the hepatocyte growth factor (HGF) and transforming growth factor beta (TGFβ) pathway. However, how exactly active hepsin promotes cell proliferation machinery to sustain tumor growth is not fully understood. Here, we show that genetic deletion of the gene encoding hepsin ( Hpn ) in a WAP‐Myc model of aggressive MYC‐driven breast cancer inhibits tumor growth in the primary syngrafted sites and the growth of disseminated tumors in the lungs. The suppression of tumor growth upon loss of hepsin was accompanied by downregulation of TGFβ and EGFR signaling together with a reduction in epidermal growth factor receptor (EGFR) protein levels. We further demonstrate in 3D cultures of patient‐derived breast cancer explants that both basal TGFβ signaling and EGFR protein expression are inhibited by neutralizing antibodies or small‐molecule inhibitors of hepsin. The study demonstrates a role for hepsin as a regulator of cell proliferation and tumor growth through TGFβ and EGFR pathways, warranting consideration of hepsin as a potential indirect upstream target for therapeutic inhibition of TGFβ and EGFR pathways in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Programs Unit/Translational Cancer Medicine Research Program and Medicum, Faculty of Medicine, University of Helsinki, Finland.
- Pathology Department, North Estonia Medical Centre, Tallinn, Estonia.
- Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA, USA.
- Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA.
- Sixfold OÜ, Tartu, Estonia.
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Finland.
ORCID-Profile: Denis Belitškin, Kati Belitškina, Juha Klefström
Zitieren
APA
Belitškin, D., Munne, P., Pant, S. M., Anttila, J. M., Suleymanova, I., Belitškina, K., Kirchhofer, D., Janetka, J., Käsper, T., Jalil, S., Pouwels, J., Tervonen, T. A., & Klefström, J. (2024). Hepsin promotes breast tumor growth signaling via the TGFβ‐EGFR axis. Molecular Oncology. https://doi.org/10.1002/1878-0261.13545
Vancouver
Belitškin D, Munne P, Pant SM, Anttila JM, Suleymanova I, Belitškina K, et al. Hepsin promotes breast tumor growth signaling via the TGFβ‐EGFR axis. Molecular Oncology. 2024. doi:10.1002/1878-0261.13545
BibTeX
@article{Belitkin2024,
author = {Belitškin, Denis and Munne, Pauliina and Pant, Shishir M and Anttila, Johanna M and Suleymanova, Ilida and Belitškina, Kati and Kirchhofer, Daniel and Janetka, James and Käsper, Taivo and Jalil, Sami and Pouwels, Jeroen and Tervonen, Topi A and Klefström, Juha},
title = {Hepsin promotes breast tumor growth signaling via the TGFβ‐EGFR axis},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13545}
}
EUVIMED